Press Releases

Aug 04, 2021
CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Durable Response Rates on Par with Autologous CD19 CAR T Therapies in CAR T Naïve Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Next CD19
Displaying 1 - 10 of 30
Print Page
Email Alerts
RSS Feeds
Investor Contacts